Quarterly report · Q3
3341.TEDINET S100Q7DI
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥232.8bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥299.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥223.4bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥5.8bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥5.8bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥5.8bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.1bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥7.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.0bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.3bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥187.6bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥178.8bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥181.9bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥131.3bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥125.9bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥56.3bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥52.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥50.2bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥20.3bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥25.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥143.23 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.64 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.56 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.57 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.14 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥10.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥10.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥4.9bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥208.1bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥208.1bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2m |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥10.6bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10m |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥602m |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥29.3bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥18.9bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.4bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥456m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥243.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥232.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥10.7bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥14.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥14.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥5.0bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥197.4bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥197.4bn |
| jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥9.1bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥6m |
| jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥423m |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥35.3bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥20.8bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥14.4bn |
| jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥237.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥223.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥14.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥10.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 364
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember | 5899000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 232844000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 232844000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember | 2000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember | 10446000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember | 10000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 10459000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -10459000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember | 208076000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember | 29316000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember | 5909000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 243303000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -10459000000 | JPY |
| Net sales | CurrentYTDDuration | 232844000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember | 10601000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember | -456000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember | 602000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 10747000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -4918000000 | JPY |
| Operating income | CurrentYTDDuration | 5829000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の4の7第1項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-02-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第43期第3四半期(自 2022年10月1日 至 2022年12月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)日本調剤株式会社 | |
| Company name in english cover page | FilingDateInstant | NIHON CHOUZAI Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 社長執行役員 三津原 庸介 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区丸の内一丁目9番1号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03-6810-0800(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員 経営企画部長 東條 祐弘 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区丸の内一丁目9番1号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03-6810-0800(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員 経営企画部長 東條 祐弘 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05422 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 33410 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)日本調剤株式会社 | |
| Filer name in english | FilingDateInstant | NIHON CHOUZAI Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |